Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for
pharmaceutical discovery and development, today announced that Shawn
O’Connor, chief executive officer, will present at the 20th Annual
B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at
10:30 a.m. (PDT) in Room 8.
The conference will be held on May 22 and 23, 2019, at The Beverly
Hilton Hotel in Beverly Hills, California, and is by invitation only.
Management will be available during the day on May 22 for one-on-one
meetings. The slides of the Company’s presentation will be available at
the Resource
Center of the Simulations Plus website (www.simulations-plus.com).
For more information, please contact 1on1@brileyfbr.com
or your B. Riley FBR representative.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery and
development software as well as a leading provider of both preclinical
and clinical pharmacometric consulting
services for regulatory submissions and quantitative
systems pharmacology models for drug-induced liver injury and nonalcoholic
fatty liver disease. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical, biotechnology, and chemical
agents. Our software is licensed to and used in the conduct of drug
research by major pharmaceutical, biotechnology, chemical, and consumer
goods companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and physiology
into our software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For more
information, visit our website at www.simulations-plus.com.
Follow us on Twitter
| LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005263/en/